Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Fast Is The Scleroderma Market Expected to Grow Between 2025 And 2029?

The value of the scleroderma market has witnessed a significant raise in the past few years. The market is expected to escalate from a worth of $2.33 billion in 2024 to $2.48 billion in 2025, with a compound annual growth rate (CAGR) of 6.6%. The progressive increase observed in the historic period is due to advancements in diagnosis methods, immunological research, therapeutic discoveries, increase in awareness and education, as well as genetic studies.

Over the upcoming years, the scleroderma market size is predicted to experience robust growth, eventually reaching $3.24 billion in 2029 with a compound annual growth rate (CAGR) of 6.9%. The anticipated growth during the forecast period can be linked to developments in biological therapies, precision medicine, stem cell therapies, as well as genomics and biomarker research, and international collaborations. The forecast period also foresees major trends like the utilization of digital health solutions, a focus on microbiomes, patient-focused care, advancements in regenerative medicine, and enhanced equity and accessibility in healthcare.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12615&type=smp

What Are the Core Growth Drivers Propelling the Scleroderma Market Forward?

The increasing incidence of scleroderma is propelling the scleroderma market. Scleroderma, a long-term autoimmune disease, is distinguished by the unusual growth of collagen that forms the structure of skin and other tissues. This disease develops due to an unchecked immune response, which could be provoked by different environmental factors. As the cases of this disease increase, the crucial need for enhanced diagnosis and treatment is becoming evident. Scleroderma treatments play an essential role in managing this disease and relieving symptoms by modulating the immune response and reducing exposure to environmental risks. For example, as reported by Karger Publishers, a Switzerland-based peer-reviewed journal publisher, the numbers revealed in June 2022 that there were 19,000 people suffering from scleroderma in the UK and 2.5 million globally. In addition, in August 2024, a study from the Oxford Academic Press, a UK-based university press associated with the University of Oxford, identified 1,588 cases of systemic sclerosis (SSc) out of 10.1 million individuals in the CPRD, which resulted in the diagnosis of 206 cancers, predominantly mucocutaneous (4.5%), lung (2.1%), and breast (1.9%). Consequently, the escalating incidence of scleroderma is fuelling the scleroderma market.

What Segment Types Define the Scleroderma Market Structure?

The sclerodermamarket covered in this report is segmented –

1) By Treatment: Medication; Surgery; Other Treatments

2) By Indication: Systemic Scleroderma; Localized Scleroderma

3) By End User: Hospital; Pharmaceutical Stores; Other End Users

Subsegments:

1) By Medication: Immunosuppressants; Antifibrotic Agents; Vasodilators; Corticosteroids; Pain Relievers

2) By Surgery: Lung Transplantation; Other Surgical Interventions

3) By Other Treatments: Physical Therapy; Occupational Therapy; Lifestyle Modifications; Alternative Therapies

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=12615&type=smp

Which Geographic Areas Hold the Strongest Growth Potential in the Scleroderma Market?

North America was the largest region in the scleroderma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the scleroderma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Which Emerging Trends that Are Influencing theScleroderma Industry Evolution?

The trend of creating new medicinal therapies is becoming increasingly well-known within the field of the scleroderma market. Top companies operating within this market are focusing on pioneering new pharmaceuticals to control symptoms and maintain their market dominance. For example, Tyr Pharma Inc., a prominent biopharmaceutical production firm based in the United States, was granted approval by the US Food and Drug Administration in April 2022 for its novel drug efzofitimod, designed to treat systemic sclerosis-related interstitial lung disease. The groundbreaking drug is a first-of-its-kind immunomodulator, which functions to regulate and manage the immune response by interacting with the neuropilin-2 (NRP2) receptor, leading to the alleviation of scleroderma symptoms. Moreover, Efzofitimod is also designed to target the identical immune cells that contribute to the pathology of SSc-ILD (interstitial lung disease related to systemic sclerosis) and lung sarcoidosis. The drug contributed to lowered markers of inflammation in a clinical trial involving patients with pulmonary sarcoidosis.

View the full report here:

https://www.thebusinessresearchcompany.com/report/scleroderma-global-market-report

What Is the Definition of the Scleroderma Market?

Scleroderma is a rare, chronic autoimmune disease characterized by the abnormal growth of collagen, a protein that forms the structure of the skin and other tissues. The different treatments cure or halt excessive collagen production, effectively manage symptoms, and reduce the risk of complications associated with scleroderma.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12615

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model